Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17137748 | 0.92 | NR1H2 (0.37) | KDM4EUSP30NR1H2CASP3BACE1 | |
| SCHEMBL4303178 | 0.87 | KDM4E (0.41) | KDM4ECASP3EGLN1EGFRGAA | |
| SCHEMBL17137484 | 0.80 | USP30 (0.36) | USP30NR1H2BACE1MEN1KMT2A | |
| SCHEMBL4309941 | 0.78 | KDM4E (0.39) | KDM4ECASP3EGLN1EGFRGAA | |
| SCHEMBL30847402 | 0.77 | USP30 (0.39) | USP30NR1H2BACE1GAAMEN1 | |
| SCHEMBL12158 | 0.77 | USP30 (0.39) | USP30NR1H2BACE1GAAMEN1 | |
| SCHEMBL31267738 | 0.76 | BACE1 (0.45) | KDM4EUSP30BACE1GAAMEN1 | |
| SCHEMBL2724339 | 0.76 | NR1H2 (0.40) | KDM4EUSP30NR1H2BACE1MEN1 | |
| SCHEMBL17137491 | 0.74 | EGLN1 (0.45) | KDM4EEGLN1 | |
| SCHEMBL482136 | 0.74 | BACE1 (0.40) | USP30NR1H2BACE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | EGLN3, EGLN2, P4HA1 | KDM4E 424/4885USP30 1556/4885NR1H2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.